Analysts Anticipate Stryker Co. (SYK) Will Announce Earnings of $1.60 Per Share

Equities research analysts expect Stryker Co. (NYSE:SYK) to post earnings of $1.60 per share for the current quarter, Zacks Investment Research reports. Eleven analysts have made estimates for Stryker’s earnings. The lowest EPS estimate is $1.58 and the highest is $1.64. Stryker posted earnings of $1.48 per share in the same quarter last year, which suggests a positive year over year growth rate of 8.1%. The firm is expected to announce its next earnings results after the market closes on Thursday, April 26th.

According to Zacks, analysts expect that Stryker will report full-year earnings of $7.12 per share for the current fiscal year, with EPS estimates ranging from $7.08 to $7.17. For the next financial year, analysts anticipate that the company will report earnings of $7.82 per share, with EPS estimates ranging from $7.69 to $7.95. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Stryker.

How to Become a New Pot Stock Millionaire

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the previous year, the firm earned $1.78 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year.

Several research analysts have recently commented on SYK shares. JPMorgan Chase upgraded Stryker from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Zacks Investment Research lowered Stryker from a “hold” rating to a “sell” rating in a report on Saturday, January 20th. Morgan Stanley lifted their price target on Stryker from $179.00 to $186.00 and gave the stock an “overweight” rating in a report on Monday, February 26th. Cantor Fitzgerald reiterated a “neutral” rating and set a $163.00 price target on shares of Stryker in a report on Friday, January 5th. Finally, Wells Fargo reiterated an “outperform” rating and set a $174.00 price target (up previously from $166.00) on shares of Stryker in a report on Tuesday, January 2nd. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and sixteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $165.27.

In other news, insider David Floyd sold 55,119 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $166.58, for a total transaction of $9,181,723.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Glenn S. Boehnlein sold 750 shares of the business’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $160.00, for a total value of $120,000.00. Following the transaction, the chief financial officer now directly owns 3,535 shares of the company’s stock, valued at $565,600. The disclosure for this sale can be found here. Insiders have sold 143,239 shares of company stock worth $23,608,485 over the last quarter. Insiders own 7.30% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Truewealth LLC acquired a new position in Stryker in the fourth quarter valued at approximately $110,000. Sawyer & Company Inc acquired a new position in Stryker in the fourth quarter valued at approximately $125,000. Sit Investment Associates Inc. boosted its holdings in Stryker by 114.3% in the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 440 shares in the last quarter. Virtue Capital Management LLC acquired a new position in Stryker in the fourth quarter valued at approximately $133,000. Finally, Oak Point Wealth Management acquired a new position in Stryker in the fourth quarter valued at approximately $145,000. 75.66% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE SYK traded up $1.02 during trading on Thursday, hitting $163.08. 637,473 shares of the company were exchanged, compared to its average volume of 1,285,219. Stryker has a 12-month low of $130.06 and a 12-month high of $170.00. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66. The firm has a market cap of $59,324.56, a PE ratio of 25.13, a P/E/G ratio of 2.28 and a beta of 0.70.

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.15%. Stryker’s dividend payout ratio (DPR) is presently 28.97%.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by registrarjournal.com and is the sole property of of registrarjournal.com. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://registrarjournal.com/2018/04/17/analysts-anticipate-stryker-co-syk-will-announce-earnings-of-1-60-per-share.html.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply